Directly attack the clinical pain points of SpA, improve the level of diagnosis and treatment, and "go to the future" together!

*For medical professionals only

A few days ago, the "To the Future" Spondyloarthritis Standardized Diagnosis and Treatment Training Program released a mid-term progress report

Spondyloarthritis (SpA) is a group of serologically negative diseases with similar clinical manifestations, including ankylosing spondylitis (AS), radiologically negative axial spondyloarthritis (nr-axSpA), psoriatic arthritis (PsA), etc

In order to promote the standardized diagnosis and treatment of SpA and improve the diagnosis and treatment level of rheumatic immune diseases in China, the National Clinical Research Center for Skin and Immune Diseases (NCRC-DID) and Peking Union Medical College Hospital jointly created a training program for the standardized diagnosis and treatment of spondylitis - "To the Future"

He stressed that strengthening the management of rheumatism patients and improving standardized diagnosis and treatment are the top

However, there is a high degree of attention to RA and SLE, and relatively little

In the case of the IL-17 inhibitor scuzidizumab, a large number of studies have shown that scuzidizumab therapy with AS can rapidly improve signs/symptoms and maintain a long-term response to therapy, effectively delaying imaging progression and reducing joint structural injury ^[4-8].

"We know that SpA is a large group of diseases, this group of diseases is very heterogeneous clinically, and there are many problems

• Establish a standardized diagnosis and treatment center to promote the development of

  
  

• Help the diagnosis and treatment center to improve the level of diagnosis and treatment, through different forms such as national training meetings, provincial training courses, famous doctors' teaching rounds/grass-roots lectures, and cutting-edge progress and guideline updates in the field of SpA, to help grass-roots clinicians improve the level of diagnosis and treatment ability and benefit more patients

  
  

• Establish a feasible chronic disease management model for spondyloarthritis, optimize and use the Data Platform of the National Rheumatology Data Center (NCRC) to conduct the first diagnosis and standardized follow-up management of patients, explore the management mode of SpA chronic diseases, improve the long-term follow-up rate of SpA patients in China, improve patient prognosis, and improve the quality of life of

  
  

Since the beginning of the year, the "Towards the Future" program has achieved fruitful results

• In February this year, 84 experts in the field of rheumatology participated in the project seminar, reached 5 meeting consensuses, clarified the guidelines and main contents of the "to the future" plan, clarified the structure, and assigned responsibility to people, laying a good foundation

  
  

• In April, the project registration was officially launched, as of now as many as 363 hospitals have participated in the project registration, and the grass-roots hospitals, prefectural and municipal third-class hospitals or B-level hospitals, and comprehensive large-scale top-three hospitals each account for one-third, with a large number and many levels, forming a hospital network with both breadth and depth, mutual help and mutual assistance, and common progress

  
  

• From May to August, a total of 22 provincial regional diagnosis and treatment training courses and 23 inter-hospital rounds were carried out, with more than 2,000 doctors participating
  .
  
  The training course and rounds teaching fully consider the actual needs of doctors, leading students to "immersive" experience clinical situations, inspire thinking, and promote communication; While imparting cutting-edge knowledge of the discipline, it also comprehensively improves the diagnosis and treatment ability of
  students.
  
  

In the remaining three months of 2022, the "To the Future" project will continue to advance steadily, and it is expected to carry out 11 regional diagnosis and treatment training courses and 25 inter-hospital rounds, and add new prefecture and city tours in Guangdong, Henan and Shandong provinces to further expand the coverage and influence
of the project.

The project team will start the project verification in October, review the work results, confirm the progress of the project, summarize the experience, and form a report
.

The "Toward the Future" project team will summarize and verify the participating hospitals, and issue the SpA standardized benchmark certificate to the qualified at the end of the year, set a benchmark for the diagnosis and treatment of rheumatology in China, and promote the popularization
of SpA standardized diagnosis and treatment through the incentive and demonstration role of "role model".

The "Towards the Future" project plans do not stop there
.

Professor Zeng Xiaofeng introduced that from 2023 to 2024, the development goals of the project include:

• Build more national clinical medical research sub-centers for skin and immune diseases at different levels, and cover the whole country through a four-level collaborative innovation network, penetrate the grass-roots level, and reach the county level and community, so as to comprehensively improve the level of diagnosis and treatment of
  rheumatic immune diseases.
  
  

• Carry out lectures on authoritative guidelines at home and abroad and "Expert Consensus on Chinese SpA Targeted Drug Therapy" throughout the country, promote the standardized diagnosis and treatment of SPA nationwide, and guide clinical practice
  according to known guidelines and consensus.
  
  

• Carry out regional/provincial/prefectural and municipal exchange meetings on the construction of rheumatic immunology disciplines, communicate with each other, learn from each other's strengths, promote the development of rheumatic immunology sciences, improve the construction of rheumatology and immunology departments and the growth of talents, and improve the overall level
  of diagnosis and treatment of rheumatic immunology disciplines.
  
  

"Rheumatology and immunology is a young discipline, especially in China, which started late, with a weak foundation and uneven
regional development.

In the new century, there have been major changes in the treatment of rheumatic immune diseases, which is a huge challenge for us and a rare opportunity
.

Professor Zeng Xiaofeng said, "We look forward to the 'to the future' project will not only promote the standardization of SpA diagnosis and treatment, benefit the majority of patients, but also drive the common progress of rheumatologists across the country and move towards a better future
together.
"
”